Amneal Pharmaceuticals Statistics
Total Valuation
AMRX has a market cap or net worth of $2.23 billion. The enterprise value is $4.93 billion.
| Market Cap | 2.23B |
| Enterprise Value | 4.93B |
Important Dates
The next confirmed earnings date is Friday, August 9, 2024, before market open.
| Earnings Date | Aug 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AMRX has 308.65 million shares outstanding. The number of shares has increased by 102.01% in one year.
| Shares Outstanding | 308.65M |
| Shares Change (YoY) | +102.01% |
| Shares Change (QoQ) | +74.46% |
| Owned by Insiders (%) | 57.00% |
| Owned by Institutions (%) | 32.43% |
| Float | 132.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.65 |
| PS Ratio | 0.90 |
| Forward PS | 0.84 |
| PB Ratio | n/a |
| P/FCF Ratio | 14.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.48, with an EV/FCF ratio of 31.60.
| EV / Earnings | n/a |
| EV / Sales | 1.98 |
| EV / EBITDA | 16.48 |
| EV / EBIT | 68.21 |
| EV / FCF | 31.60 |
Financial Position
The company has a current ratio of 1.65
| Current Ratio | 1.65 |
| Quick Ratio | 0.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | 9.18 |
| Debt / FCF | 17.60 |
| Interest Coverage | 0.32 |
Financial Efficiency
Return on equity (ROE) is -111.50%.
| Return on Equity (ROE) | -111.50% |
| Return on Assets (ROA) | -4.70% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $324,059 |
| Profits Per Employee | -$21,908 |
| Employee Count | 7,700 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.94 |
Taxes
In the past 12 months, AMRX has paid $13.94 million in taxes.
| Income Tax | 13.94M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +124.85% in the last 52 weeks. The beta is 1.23, so AMRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +124.85% |
| 50-Day Moving Average | 6.80 |
| 200-Day Moving Average | 5.59 |
| Relative Strength Index (RSI) | 59.43 |
| Average Volume (20 Days) | 1,582,309 |
Short Selling Information
The latest short interest is 4.52 million, so 1.46% of the outstanding shares have been sold short.
| Short Interest | 4.52M |
| Short Previous Month | 3.61M |
| Short % of Shares Out | 1.46% |
| Short % of Float | 3.41% |
| Short Ratio (days to cover) | 2.47 |
Income Statement
In the last 12 months, AMRX had revenue of $2.50 billion and -$168.69 million in losses. Loss per share was -$0.73.
| Revenue | 2.50B |
| Gross Profit | 880.44M |
| Operating Income | 142.33M |
| Pretax Income | -154.75M |
| Net Income | -168.69M |
| EBITDA | 299.04M |
| EBIT | 72.26M |
| Loss Per Share | -$0.73 |
Balance Sheet
The company has $51.62 million in cash and $2.75 billion in debt, giving a net cash position of -$2.69 billion or -$8.73 per share.
| Cash & Cash Equivalents | 51.62M |
| Total Debt | 2.75B |
| Net Cash | -2.69B |
| Net Cash Per Share | -$8.73 |
| Equity (Book Value) | -63.72M |
| Book Value Per Share | -0.21 |
| Working Capital | 545.66M |
Cash Flow
In the last 12 months, operating cash flow was $201.46 million and capital expenditures -$45.46 million, giving a free cash flow of $155.99 million.
| Operating Cash Flow | 201.46M |
| Capital Expenditures | -45.46M |
| Free Cash Flow | 155.99M |
| FCF Per Share | $0.51 |
Margins
Gross margin is 35.28%, with operating and profit margins of 5.70% and -6.76%.
| Gross Margin | 35.28% |
| Operating Margin | 5.70% |
| Pretax Margin | -6.20% |
| Profit Margin | -6.76% |
| EBITDA Margin | 11.98% |
| EBIT Margin | 2.90% |
| FCF Margin | 6.25% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.01% |
| Shareholder Yield | -102.01% |
| Earnings Yield | -7.55% |
| FCF Yield | 6.98% |
Analyst Forecast
The average price target for AMRX is $8.00, which is 10.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 10.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 3.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMRX has an Altman Z-Score of 1.13 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.13 |
| Piotroski F-Score | 5 |